These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 2123300)

  • 1. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. recombinant Factor VIII Study Group.
    Schwartz RS; Abildgaard CF; Aledort LM; Arkin S; Bloom AL; Brackmann HH; Brettler DB; Fukui H; Hilgartner MW; Inwood MJ
    N Engl J Med; 1990 Dec; 323(26):1800-5. PubMed ID: 2123300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group.
    Lusher JM; Arkin S; Abildgaard CF; Schwartz RS
    N Engl J Med; 1993 Feb; 328(7):453-9. PubMed ID: 8421474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A.
    Hsu HC; Chen YF; Ho CH
    Zhonghua Yi Xue Za Zhi (Taipei); 1999 Jul; 62(7):450-4. PubMed ID: 10418180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors.
    Santagostino E; Morfini M; Rocino A; Baudo F; Scaraggi FA; Gringeri A
    Thromb Haemost; 2001 Oct; 86(4):954-8. PubMed ID: 11686352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical evaluation of recombinant human factor VIII (BAY w 6240) in the treatment of hemophilia A.
    Fukui H; Yoshioka A; Shima M; Tanaka I; Koshihara K; Fukutake K; Fujimaki M
    Int J Hematol; 1991 Oct; 54(5):419-27. PubMed ID: 1756252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy, Safety, and Pharmacokinetics of Beroctocog Alfa in Patients Previously Treated for Hemophilia A.
    Hyun SY; Park SY; Lee SY; Kook H; Paik SH; Jang IJ; Lee KS
    Yonsei Med J; 2015 Jul; 56(4):935-43. PubMed ID: 26069114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical efficacy, safety and pharmacokinetic properties of the factor VIII concentrate Haemoctin SDH in previously treated patients with severe haemophilia A.
    Wolf DM; Rokicka-Milewska R; Lopaciuk S; Skotnicki AB; Klukowska A; Laguna P; Windyga J; Kotitschke R; Struff WG
    Haemophilia; 2004 Sep; 10(5):438-48. PubMed ID: 15357768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Recombinant activated Factor VII (Novoseven Novo Nordisk) for hemostasis in acquired Factor VIII-inhibitor hemophilia].
    Meili EO; Dazzi H; von Felten A
    Schweiz Med Wochenschr; 1995 Mar; 125(9):405-11. PubMed ID: 7892567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics, efficacy and safety of IMMUNATE solvent/detergent (IMMUNATE S/D) in previously treated patients with severe hemophilia A: results of a prospective, multicenter, open-label phase III study.
    Nemes L; Lissitchkov T; Dobaczewski G; Klukowska A; Komrska V; Zimmermann R; Auerswald G; Engl W; Abbühl B; Pavlova BG; Ehrlich HJ
    Acta Haematol; 2008; 119(2):89-97. PubMed ID: 18305381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of IgG antibodies to human parvovirus B19 in haemophilia children treated with recombinant factor (F)VIII only or with at least one plasma-derived FVIII or FIX concentrate: results from the French haemophilia cohort.
    Gaboulaud V; Parquet A; Tahiri C; Claeyssens S; Potard V; Faradji A; Peynet J; Costagliola D;
    Br J Haematol; 2002 Feb; 116(2):383-9. PubMed ID: 11841442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hemophilia. Strategies for the treatment of inhibitor patients.
    Ingerslev J
    Haematologica; 2000 Oct; 85(10 Suppl):15-20. PubMed ID: 11187863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicenter study of recombinant factor VIII (Recombinate) in previously treated patients with hemophilia A. The Recombinate Previously Treated Patient Study Group.
    White GC; Courter S; Bray GL; Lee M; Gomperts ED
    Thromb Haemost; 1997 Apr; 77(4):660-7. PubMed ID: 9134639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elective surgery on factor VIII inhibitor patients using continuous infusion of recombinant activated factor VII: plasma factor VII activity of 10 IU/ml is associated with an increased incidence of bleeding.
    Smith MP; Ludlam CA; Collins PW; Hay CR; Wilde JT; Grigeri A; Melsen T; Savidge GF
    Thromb Haemost; 2001 Oct; 86(4):949-53. PubMed ID: 11686351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Current status and future prospects of hemophilia treatment].
    Lopaciuk S
    Acta Haematol Pol; 1995; 26(2 Suppl 1):44-55. PubMed ID: 7653234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitor antibodies to factor VIII and factor IX: management.
    Lusher JM
    Semin Thromb Hemost; 2000; 26(2):179-88. PubMed ID: 10919411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic properties of recombinant factor VIII compared with a monoclonally purified concentrate (Hemofil M). The Recombinate Study Group.
    Morfini M; Longo G; Messori A; Lee M; White G; Mannucci P
    Thromb Haemost; 1992 Oct; 68(4):433-5. PubMed ID: 1448776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of factor VIII/von Willebrand's factor concentrate (Haemate-P) in preventing bleeding during surgery or invasive procedures in patients with von Willebrand disease.
    Franchini M; Rossetti G; Tagliaferri A; Pattacini C; Pozzoli D; Lippi G; Manzato F; Bertuzzo D; Gandini G
    Haematologica; 2003 Nov; 88(11):1279-83. PubMed ID: 14607757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of the intron 22 inversion of the factor VIII gene and inhibitor development in Polish patients with severe hemophilia A.
    Sawecka J; Skulimowska J; Windyga J; Lopaciuk S; Kościelak J
    Arch Immunol Ther Exp (Warsz); 2005; 53(4):352-6. PubMed ID: 16088320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment and prevention of acute bleedings in von Willebrand disease--efficacy and safety of Wilate, a new generation von Willebrand factor/factor VIII concentrate.
    Berntorp E; Windyga J;
    Haemophilia; 2009 Jan; 15(1):122-30. PubMed ID: 19149848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of factor VIII concentrates on the immune system of patients with hemophilia.
    Mannucci PM
    Thromb Haemost; 1995 Jul; 74(1):437-9. PubMed ID: 8578501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.